Src Mutation Induces Acquired Lapatinib Resistance in ERBB2-Amplified Human Gastroesophageal Adenocarcinoma Models

• Yong Sang Hong,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  ⨯
• Jihun Kim,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  ⨯
• Eirini Pectasides,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Cameron Fox,

  Affiliation Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Seung-Woo Hong,

  Affiliation Innovative Cancer Research, Asan Institute for Life Science, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  ⨯
• Qiuping Ma,

  Affiliation Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Gabrielle S. Wong,

  Affiliation Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Shouyong Peng,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Cancer Program, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America

  ⨯
• Matthew D. Stachler,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America

  ⨯
• Aaron R. Thorner,

  Affiliation Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Paul Van Hummelen,

  Affiliation Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Adam J. Bass

  * E-mail: adam_bass@dfci.harvard.edu

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Cancer Program, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America

  ⨯